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Background

Every year approximately 3,500 new cases of pediatric Acute Lymphoblastic Leukemia
(ALL) are diagnosed.1 ALL is characterized by an accumulation of immature B or T
lymphocytes, known as blasts, in the bone marrow and blood. ALL originates in the bone
marrow where hematopoietic stem cells differentiate into either myeloid or lymphoid stem cells.
Lymphoid stem cells further convert into immature cells called lymphoblasts, and the
lymphoblasts typically further differentiate into mature B or T lymphocytes. Because of the
proliferation of immature white blood cells in ALL, normal healthy white blood cells can
become crowded out, leading to a variety of possible symptoms. A child with ALL may display
signs and symptoms such as bone or joint pain, fever, frequent infections, loss of appetite,
fatigue, easy bruising, shortness of breath, swollen lymph nodes (painless lumps in the neck,
underarm, groin, or abdomen), and petechiae (small, flat dark spots due to bleeding under the
skin).
Approximately 25% of all cancers diagnosed before age 15 are ALL, and ALL comprises
19% of cancers among all patients under age 20.2 These statistics make ALL the most common
pediatric cancer and most frequent cancer-induced cause of death among patients under the age
of 20.3 Despite these grim facts, successful treatment of ALL has undergone remarkable progress
within the last 50-60 years. In 1964, survival rates for children with ALL hovered around 10%.4
Improvements in survival outcomes have continued in the decades since. Analyses from 19751979 indicated a 5-year survival rate for childhood and adolescent ALL patients of 56.8%.
Subsequent analyses showed 5-year survival rates of 74.9% from 1985-1989 and 83.8% from
1995-1999.5 Between 1990-1994 1,194 ALL patients died, while 882 died between 1995 and
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1999, and 687 died between 2000 and 2005. In the period from 2000-2005, 5-year survival rates
rose to 90.4%, representing a towering achievement in medical progress and collaboration within
just five decades.6 Improved risk stratification, personalized chemotherapy, and further postinduction failure treatments promise to further enhance the survival rates of patients.

Incidence

According to Ward et al. males are diagnosed at a higher rate than females (38.4 for
males and 30.2 for females where all rates are given per 1,000,000). ALL is more commonly
diagnosed in highly industrialized nations, where there is a spike in ALL incidence rates between
ages 2-4. However, the spike is much more pronounced in non-Hispanic white and Hispanic
children than black children (about 110 for Hispanics, 105 for whites, and 40 for blacks).
Hispanics are diagnosed at the highest rates altogether, followed by non-Hispanic whites, Asians
and Pacific Islanders, and non-Hispanic blacks (rates are 44.9, 34.2, 28.7, and 18.3,
respectively). Though less black children are diagnosed with ALL, disparities in survival rates
have long been documented. From 1980-1984 the 5-year survival rate disparity between whites
and blacks was a 21% difference (68% survival for whites, 47% for blacks). However, this
disparity has decreased sharply over the last few decades to a 6% difference in survival from
2003-2009 (90% for white, 84% for blacks).7 This disparity may have to do with blacks having
elevated incidence rates of T-cell based ALL, which is considered a high-risk feature relative to
B-cell precursor ALL. One favorable prognostic indicator of ALL is hyperdiploidy, which is
found in low frequencies in black Americans.8 A study by Hunger et al. of the Children’s
Oncology Group (COG) reported that during the period from 2000-2005, 44.5% of blacks had
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NCI (National Cancer Institute) high-risk classification group features while just 32.9% of nonHispanic whites had NCI high-risk classification features. Hispanics were at a 1.5x higher risk of
death than non-Hispanics during the period studied.6 This is likely a result of much higher
incidences of particular genomic aberrations in leukemic cells among Hispanics enrolled in COG
ALL trials.9 The reason for higher rates of total incidence in Hispanic populations is currently
unknown. Recent studies have examined genetic susceptibility, increasing trends in obesity
among Hispanics, and disproportionate exposure to household chemicals.10

Risk Stratification

ALL is a model disease for the utilization of risk-based therapy, and the risk of treatment
failure determines stratification of treatment intensity. There are several key identifying features
of ALL that affect classification and prognosis. Patients with less debilitating features are treated
with less toxic regimens, and conversely, those with profiles of higher-risk disease receive more
aggressive treatment regimens.11 In relatively recent years, a renewed emphasis has been placed
on identifying the features that routinely affect prognosis. In 1993, the NCI sponsored a
workshop in order to define the criteria for risk-based stratification treatment. Workshop
participants included physicians and scientists from the COG, Pediatric Oncology Group, DanaFarber Cancer Institute, and St. Jude Children’s Research Hospital. Based on ALL clinical trials
and data outcomes of different groups, the NCI group concluded that B-cell precursor patients
(which make up the vast majority of ALL patients) between ages 1-10 with a presenting white
blood cell (WBC) count at diagnosis of less than 50,000 cells/microliter would comprise the
standard-risk category.12 All other patients are classified into the high-risk ALL group (namely
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those less than 1 year of age, older than 10 years of age, or with an initial WBC greater than
50,000 cells/microliter). Additionally, patients taking corticosteroids prior to their diagnostic
blood workup are automatically considered high-risk due to the confounding effects of steroids
on WBC count.11
Different conclusions have resulted from different treatment strategies for T-cell ALL,
and consequently, some institutions automatically label these patients as high risk while other
institutions continue to rely on classification by age and WBC count for T-cell patients. Hunger
et al. found that among 21,626 children and adolescents from 1990-2005, patients with T-cell
ALL had a higher risk of death than patients with B-cell ALL. Additionally, patients classified as
NCI high risk ALL individuals had a 2.4-3.6 fold increased risk of death when compared with
NCI standard risk patients.6 Overall, there is consensus that by improving the uniformity of risk
stratification based therapy, the efficiency of forthcoming ALL research will also improve.

Genetics

Conventionally, the NCI risk stratification features of patient age and WBC count at
diagnosis have shown the most consistent predictive power. However, numerous other clinical
and biologic factors have been scrutinized for prognostic value, though few remain after
multivariate analysis.13 Leukemic cell chromosomal number has been one of the factors to
routinely appear prognostic, with some research suggesting that the presence of additional
specific chromosomes may be more noteworthy than a general increase in total ploidy. There are
also several genetic abnormalities that are associated with better or worse outcomes. However,
there is generally no consensus on how to incorporate many of the more specific and novel
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genetic component findings of the disease into high or standard-risk stratification groups, and
this is due in part to the relatively recent advent of genome-wide analysis of patients which is
necessary to find these potentially prognostic genetic profiles.14 This lack of consensus can be
further attributed to inconsistent findings among clinical trial groups when modifying treatment
plans for a specific genetic abnormality. Distinct genetic irregularities are identified in
approximately 75-80% of pediatric ALL cases with typical chromosomal and molecular genetic
analyses, but through the use of genome-wide analysis, genetic abnormalities are found in
virtually all cases.14 Beyond specific mutations in genes that regulate different hematopoietic
aspects, two well-documented genetic anomalies associated with better or worse outcomes are
hypodiploidy and hyperdiploidy. Hyperdiploidy has been associated with favorable outcomes,
while hypodiploidy is strongly associated with poor outcomes.

Hyperdiploidy

In about 20-25% of B-cell precursor ALL, patients present with high hyperdiploidy
(defined as 51 to 65 chromosomes per leukemic cell or a DNA index of greater than 1.16).11
DNA index is a prognostic factor used specifically in childhood ALL which measures the
chromosomal material of cancerous cells.15 In 2005, Sutcliffe et al. published a paper in which
two independent groups, the Children’s Cancer Group (CCG) and the Pediatric Oncology Group
(POG), examined the significance of three specific trisomies (a type of chromosomal
abnormality in which there are three copies of a particular chromosome instead of the usual two).
The two groups both analyzed populations of patients with NCI standard and high-risk
stratification classifications. A total of 5,484 patients were analyzed (1,582 by the CCG and
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3,902 by the POG), and eight-year event free survival rates (EFS) of 91% (CCG) and 89%
(POG) were reported in patients assigned to the standard risk classification groups whose
leukemic cells had concurrent trisomies of chromosomes 4, 10, and 17. Further analysis from the
POG showed that hyperdiploidy in general was less of a significant favorable prognostic factor
without the three crucial trisomies, and this finding supports the conclusions of previous POG
and CCG studies in which results indicated that specific trisomies hold more favorable
prognostic weight than general chromosome number for predicting outcome in the same patient
type (pediatric B-precursor ALL patients).16 For the NCI high-risk classification patients from
the sample population, no prognostic significance was found regarding the number of agreeable
trisomies.17

Hypodiploidy

Hypodiploidy (defined as having a modal leukemic cell chromosomal number below 46
or a DNA index of less than 0.81) has been found to be strongly associated with poor outcomes
in pediatric ALL patients. Nachman et al. analyzed data on 139 hypodiploid patient cases
gathered from 10 different cooperative groups and institutions. Patients were grouped based on
chromosomal number of leukemic cells and 4 categories resulted: 24-29 chromosomes (n=46),
33-39 chromosomes (n=13), 40-43 chromosomes (n=13), and 44 chromosomes (n=54). Again,
eight-year EFS rates were analyzed and determined to be just 38.5% ± 4.4% overall. No
substantial differences were found in outcomes for patients from the 24-29, 33-39, or 40-43
chromosome groups, but the 44 chromosome group independently had eight-year EFS rates of
52.2% compared to 30.1% for the remaining three groups collectively. Patients in the 44
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chromosome group had worse EFS rates if they had a monosomy 7, dicentric chromosome (an
abnormality in which a chromosome has two centromeres), or both.18 Though hypodiploid
patients with 45 chromosomes in their leukemic cells were not analyzed in the previously
discussed study, they have been shown to have significantly better outcomes than those
hypodiploid patients with less than 45 chromosomes in their leukemic cells.19

Treatment

Response to initial treatment therapy is also considered to be an especially reliable and
independent prognostic indicator. Remission induction is the goal of the first of three major
components of treatment in recently diagnosed ALL patients (some publications consider there
to be four major components, and all four aspects will be discussed). Complete remission (the
goal of induction) is usually defined to mean that less than 5% of immature blast cells remain in
a patient’s bone marrow, and the vast majority of patients achieve this initial milestone.

Induction

According to pediatric hematology oncology physicians Stacy Cooper and Patrick
Brown, induction therapy typically lasts 4-6 weeks and consists of chemotherapy with the drugs
vincristine, anthracycline (doxorubicin or daunorubicin), asparaginase, and corticosteroids
(prednisone or dexamethasone). Patients are typically admitted to the hospital before beginning
treatment, but barring any complications, patients may be discharged and continue treatment as
outpatients. Severe infections are more likely during this phase of treatment.11 Additionally,
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relapse has been shown to occur universally without additional treatment, necessitating the
subsequent two phases.20

Consolidation

In those that successfully achieve remission, the next treatment phase is known as
consolidation and aims to further reduce the presence of leukemic cells throughout the body.
This phase lasts about 6-9 months but is dependent upon risk classification of the patient and
which specific cancer group’s protocol is being followed. Consolidation generally occurs in an
outpatient setting. Those patients with higher-risk classifications would typically receive longer
and stronger drug regimens. Some of the primary chemotherapeutic drugs used are
mercaptopurine, thioguanine, methotrexate, cyclophosphamide, etoposide, and cytarbine. These
drugs differ from those of the induction phase and are used in certain combinations to improve
collective effectiveness and reduce drug resistance. Higher risk patients may receive a second
burst of intense chemotherapy within the consolidation phase known as delayed intensification.11

Maintenance

If the patient remains in remission after both the induction and consolidation phases, then
the final and longest phase of treatment can commence, known as maintenance. Maintenance is
significantly longer and less intense than the prior two phases and has been demonstrated to
reduce the risk of relapse after remission has been achieved.11 However, the precise explanations
for why maintenance is a necessary phase and the most effective composition of maintenance
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have yet to be fully elucidated.20 Furthermore, due to the extensive length (2-3 years) and daily
requirements of the phase, there are issues with patient adherence. Approximately 20% of
patients are less than 90% adherent, and unfortunately adherence of less than 90% is associated
with a relapse risk four times higher than patients who are over 90% adherent.21 Maintenance
treatment is based primarily around antimetabolite therapy with the drugs methotrexate (weekly,
oral) and mercaptopurine or thioguanine (daily, oral).11 Individual metabolic differences are
becoming increasingly notable in how they affect the use of these drugs during maintenance.

Intrathecal Therapy

As previously mentioned, some publications consider there to be a fourth phase of
standard treatment which involves therapy directed specifically against the central nervous
system (CNS). Three different methods can be utilized to expunge signs of disease from the
CNS, and these include cranial irradiation, systemic chemotherapy capable of penetrating the
blood-brain barrier, and direct intrathecal chemotherapy administration. Most treatment groups
begin using intrathecal chemotherapy upon induction of remission. Other groups use protocols
using intrathecal therapy throughout the treatment process while others do not utilize it during
the maintenance phase.11 During the 1960s and 1970s, cranial irradiation drastically increased
cure rates in ALL patients. However, it was associated with some increased risk of secondary
CNS tumors and neurocognitive effects, particularly with younger patients.22 For these reasons
the use of cranial irradiation has been progressively declining, and it is generally reserved for
those patients with the highest risk of CNS relapse. Multiple research groups have implemented
treatment protocols eliminating CNS irradiation entirely for almost all newly diagnosed patients
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and have seen results similar to those reported by research groups who continue to use irradiation
treatment. The use of cranial irradiation remains controversial, but currently all research groups
treat approximately 80% of pediatric patients without CNS irradiation.23

Treatment Failure

Induction failure and relapse are the primary avenues by which treatment may fail.
Relapse is more common and has experienced little progress in treatment strategies in contrast
with the increasingly improving outcomes of newly diagnosed ALL patients.24 Though induction
failure is rarer, it portends more unfavorable outcomes.

Induction Failure

Cooper and Brown report that failure to reach remission after initial induction therapy
occurs in 3-5% of pediatric ALL patients and forebodes a particularly dismal prognosis –
approximately 33% overall survival (OS) rates, making induction failure one of the most
unfavorable possible outcomes during pediatric ALL treatment.11 About 95% of patients do
reach this important prognostic benchmark of initial complete remission, but for those who do
not, risk stratification promptly changes. Due to the rarity of induction failure, those who do not
achieve remission are almost always reclassified into a third risk subgroup, very-high-risk. A
study by Schrappe et al. examined data from 14 different study groups on 44,017 patients
between the ages of 0-18 who were recently diagnosed with ALL and had begun treatment.
1,041 of the total patients experienced induction failure. The study defined induction failure as
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leukemic blast persistence in the bone marrow, blood, or any extramedullary location between 28
and 43 days after beginning treatment. Various treatment strategies were employed for induction
failure patients among the study groups analyzed. Treatments utilized included additional
chemotherapy, clinical trial enrollment, and hematopoietic stem cell transplantation (HSCT). The
primary conclusion upon statistical analysis of outcomes and patient data is that there is
tremendous clinical and biologic heterogeneity among patients who experience induction
failure.25

Relapsed Disease

Of those who successfully complete induction therapy and advance to further treatment
phases, approximately 15-20% of ALL patients experience relapsed disease, and cure rates are
significantly lower following relapse.26 Relapse is the most common cause of treatment failure,
and like newly diagnosed patients, relapsed ALL patients are risk stratified. Stratification now
depends primarily upon the length of the first remission and the location of relapse within the
body (marrow relapses are the most common). Cooper and Brown report that late relapses
occurring greater than three years after diagnosis have the best prognosis, while relapses between
18-36 months are given an intermediate prognosis, and those within 18 months of diagnosis have
the worst outcomes.11 HSCT is used in greater than 50% of relapsed patients, but there are
multiple different treatment strategies, again depending on which treatment group’s care the
patient is under.27 There has been a greater influx in recent years of research investigating the
biology of relapse, antibody-based therapies, and other immunological approaches.24

Geierman 12
New Treatments and the Optimistic Future of ALL

Blinatumomab and chimeric antigen receptor (CAR) T cell therapy are two new
innovative immunotherapies that have demonstrated success in treating patients with relapsed or
refractory ALL. Refractory patients are typically defined as those patients that have relapsed and
had a second round of additional therapy fail as well. Advances in genomic technology and
personalized medicine also show promise in the future treatment of ALL.

Blinatumomab

Blinatumomab (a monoclonal antibody) is a bispecific T-cell engager (BiTE) that exerts
its effect by facilitating interaction between a patient’s own T and B cells. Blinatumomab
contains binding sites for two distinct targets: the CD19 antigen on B cells and the CD3 site on T
cells. By linking both of these cell types, blinatumomab facilitates the activation and production
of cytotoxic effects by T cells. The drug binds to both benign and malignant cells of B-lineage
origin. Lysis of CD19-positive cells is directed by the proliferation of T cells and release of
inflammatory cytokines and cytolytic proteins.28,29
In 2016, von Stackelberg et al. published the results of a Phase I/Phase II clinical trial of
blinatumomab in pediatric patients who had relapsed or refractory ALL. The study was the first
of its kind in pediatrics and evaluated the safety, pharmacokinetics, recommended dosage, and
potential for efficacy of the drug. 49 patients (all under the age of 18) were treated in phase I and
a recommended dosage was determined. 44 patients were treated in phase II, and a total of 70
received the recommended dosage. 27 patients achieved complete remission (CR) within the first
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two cycles of drug administration. However, at the end of a 2-year follow-up, of the 27 who
achieved CR 4 were still in remission. Two had relapsed but were alive, three had withdrawn
consent, three died in CR after receiving HSCT, and fifteen had relapsed and died. Further
investigation of blinatumomab is supported based upon the anti-leukemic activity of the drug.30

CAR-T Cell Therapy

On August 30th, 2017, tisagenlecleucel (CD19 directed CAR-T cell therapy) was
approved by the FDA for certain pediatric and young adult cancer patients, making it the first
gene therapy available in the United States. This therapy works by genetically modifying a
patient’s own T-cells so that they can locate and destroy cancerous B cells. The T cells are
removed from the patient, mailed to a manufacturing center, and genetically altered so that they
are able to display a specific receptor (a chimeric antigen receptor, or CAR). The cells are then
infused back into the patient. The CAR receptors on the modified T cells direct them to bind to
and kill B cells displaying the CD19 antigen.31 A phase I/II study of CAR-T cell therapy
conducted by the Children’s Hospital of Philadelphia and the University of Pennsylvania showed
a CR rate of 90% among 30 children with relapsed or refractory ALL.32 In 2018, a second
comprehensive study of tisagenlecleucel was conducted. The phase II clinical trial was a global,
25 center collaborative study conducted in relapsed or refractory ALL patients between the ages
of 3 and 21. 75 patients received treatment, and the overall remission rate was 81% while 45
patients attained complete remission. The rates of OS and EFS were 90% and 73% respectively
at 6 months and 76% and 50% at 12 months. There are substantial, though primarily transient,
risks associated with the therapy, namely cytokine release syndrome (CKS).33 High fever can
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result from CKS, and in some situations can progress to respiratory and cardiovascular
compromise. However, there has been success in treating CKS with the drugs etanercept and
tocilizumab.34 Overall, the use of tisagenlecleucel resulted in high remission rates, and though
side effects can be severe, they can be mitigated in most patients.

Genome-wide Analysis

Partly in response to the tremendous heterogeneity of patients who experience treatment
failure, whether it be through relapse or induction failure, there has been a significant amount of
ALL research focusing on the identification of genetic alterations and the development of new
classification subtypes. Recent research with genome-wide analysis has also identified clinically
relevant and novel genetic abnormalities that could serve as treatment targets. These advances in
biomedical technology are a promising sign of the legitimacy of personalized treatment plans
maximizing drug effectiveness and minimizing toxicity based individually on distinct genetic
profiles.35
Acute Lymphoblastic Leukemia has become a representative success story of the
triumphs of modern medicine. Before 1960, for the vast majority of patients a diagnosis of ALL
was essentially a death sentence. Survival rates hovered around an abysmal 10%, and thousands
of children died every year from the disease. Today, overall survival rates for newly diagnosed
patients are approximately 90%. This sharp contrast can be attributed to the relentless pursuit of
research on treatments and the different profiles in which the disease manifests. The
development of chemotherapeutic agents and the elucidation of the optimal administration of
these agents have presumably afforded many thousands of children the opportunity to live out
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their lives. Unfortunately, many patients still die from ALL and its complications, but continued
research, innovation, and advances in immunotherapy, genomics, and personalized medicine
provide legitimate reason for optimism about the future outlook of ALL patients who have
experienced treatment failure. It is not unforeseeable that a day could soon arise when using high
throughput genomic sequencing, chemotherapy, immunotherapy, and personalized treatment
plans that all patients could have a legitimate chance of cure.
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